Accessibility Menu
 
Intellia Therapeutics logo

Intellia Therapeutics

(NASDAQ) NTLA

Current Price$14.35
Market Cap$1.59B
Since IPO (2016)-39%
5 Year-81%
1 Year+99%
1 Month+4%

Intellia Therapeutics Financials at a Glance

Market Cap

$1.59B

Revenue (TTM)

$67.67M

Net Income (TTM)

$412.69M

EPS (TTM)

$-3.83

P/E Ratio

-3.53

Dividend

$0.00

Beta (Volatility)

1.93 (High)

Price

$14.35

Volume

1,363,117.664

Open

$13.30

Previous Close

$13.49

Daily Range

$13.30 - $14.28

52-Week Range

$6.73 - $28.25

NTLA: Motley Fool Moneyball Superscore

52

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Intellia Therapeutics

Industry

Biotechnology

Employees

377

CEO

John M. Leonard, MD

Headquarters

Cambridge, MA 02139, US

NTLA Financials

Key Financial Metrics (TTM)

Gross Margin

-26%

Operating Margin

-7%

Net Income Margin

-6%

Return on Equity

-53%

Return on Capital

-60%

Return on Assets

-49%

Earnings Yield

-28.33%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.59B

Shares Outstanding

118.13M

Volume

1.36M

Short Interest

0.00%

Avg. Volume

4.55M

Financials (TTM)

Gross Profit

$51.75M

Operating Income

$440.99M

EBITDA

$396.77M

Operating Cash Flow

$348.88M

Capital Expenditure

$5.78M

Free Cash Flow

$354.66M

Cash & ST Invst.

$449.88M

Total Debt

$93.33M

Intellia Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$23.02M

+78.8%

Gross Profit

$17.00M

+32.1%

Gross Margin

73.87%

N/A

Market Cap

$1.59B

N/A

Market Cap/Employee

$3.95M

N/A

Employees

403

N/A

Net Income

$95.79M

+25.7%

EBITDA

$95.41M

+28.7%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$356.56M

-8.9%

Accounts Receivable

$9.47M

+11.2%

Inventory

$0.00

N/A

Long Term Debt

$66.85M

-64.8%

Short Term Debt

$26.48M

+30.8%

Return on Assets

-49.01%

N/A

Return on Invested Capital

-59.74%

N/A

Free Cash Flow

$69.41M

+19.5%

Operating Cash Flow

$69.28M

+18.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PHVSPharvaris N.V.
$27.36+2.75%
WVEWave Life Sciences Ltd.
$7.18-0.03%
ZYMEZymeworks Inc.
$26.12-0.76%
BCRXBioCryst Pharmaceuticals, Inc.
$9.43-1.41%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$10.78+0.02%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$6.45+0.00%
TQQQProShares Trust - ProShares UltraPro Qqq
$50.13+0.02%
PLTRPalantir Technologies
$132.34+0.03%

Questions About NTLA

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.